BAMF
SMMT icon

BI Asset Management Fondsmaeglerselskab’s Summit Therapeutics SMMT Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-125,100
Closed -$2.66M – 765
2025
Q2 		$2.66M Buy
+125,100
New +$2.85M 0.03% 321

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's SMMT Position: Q3 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 125,100 shares — an estimated $2.66M sold.

BI Asset Management Fondsmaeglerselskab first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $2.66M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 125,100 Summit Therapeutics shares in Q3 2025, an estimated $2.66M.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Summit Therapeutics position peaked at $2.66M in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q3 2025, filed 5 Nov 2025.